title: What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation?
authors.forename: Frédéric
authors.initials: F
authors.lastname: Lamoth
authors.forename: Oriol
authors.initials: O
authors.lastname: Manuel
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Venetz
authors.forename: Mohamed
authors.initials: M
authors.lastname: Faouzi
authors.forename: Pascal
authors.initials: P
authors.lastname: Meylan
authors.forename: Manuel
authors.initials: M
authors.lastname: Pascual
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation; D009894:Opportunistic Infections / Q000453:epidemiology / Q000517:prevention & control; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir